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21.91%, p< 0.01), compared to those without a PD diagnosis. The PD cohort also 
incurred significantly higher skilled nursing facility ($6,458 vs. $5,182, p= 0.03), DME 
($344 vs. $206, p< 0.01) and pharmacy costs ($6,025 vs. $4,998, p< 0.0001) compared 
to the comparison cohort. ConClusions: Study results suggest that patients 
diagnosed with PD incurred significantly higher costs and had higher resource 
utilization than those without a PD diagnosis.
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objeCtives: To describe the medical and non-medical direct costs of PD in rela-
tion to the total direct cost and its variation with disease severity during 4 years 
of follow-up. Methods: A descriptive, observational, longitudinal study in PD 
patients belonging to the ELEP study (2007-2010). Data on disease severity and use 
of resources were collected for three consecutive months, yearly, for 4 years. Direct 
medical (funded medical equipment, medications and medical assistance) and 
direct non-medical costs (alternative care, home assistance, non-funded medical 
equipment and medications) for 4 years depending on severity by Hoehn and Yahr 
(HY) was described. Costs were estimated by multiplying rates obtained from the 
database Oblikue (http://www.oblikue.com) and pharmacy costs from the BotPlus 
Web (https://botplusweb.portalfarma.com) by the number of resources used, 
updated to Spanish € , 2012. Results: 198 patients were included. Average age: 
63±11 years, 50% male, mean PD duration of 8±6 years. Mild (HYI-II) and moderate 
(HYIII) PD varied from 76% and 21% to 64% and 29%, respectively during follow-up. 
Total direct cost was higher in severe stages, being in year 4, € 1,477.32 HYI (95%CI: 
219.55-2,735.10) and € 3,606.66 HYIV (95%CI: 893.97-6,319.35) compared to year 1, 
€ 1,093.32 HYI (95%CI: 624.99-1,561.65) to € 2,656.27 HYIV (95%CI: -53.14-5,365.68). 
Direct medical costs ranged from € 886.62 (95%CI: 475.13-1,298.11) HYI and € 2,376.30 
HYIV (95%CI: -53.12-4,805.73) in year 1 to € 909.96 HYI (95%CI: 942.43-1,327.49) and 
€ 2,768.49 HYIV (95%CI: 34.21-5,502.76) at year 4. Direct non-medical cost variation 
were determined by PD temporal evolution, increasing between year 1 and 4 within 
each stage, € 723.47 to € 4,255.20 HYI and € 653.27 to € 1,676.35 HYIV. ConClusions: 
The economic burden of PD rises with duration and severity of the disease, progres-
sively increasing the direct, medical and non-medical costs. Besides to improve 
patients’ HRQoL, therapies aimed at controlling the symptoms severity will favor a 
more efficient management of the disease.
PND30
Does cuRReNt PoRtuguese fiNaNciNg MoDel foR MultiPle scleRosis 
coveRs foR estiMateD NeeDs?
Montóia B.1, Guerreiro T.1, Viana R.2
1Novartis Farma – Produtos Farmaceuticos S. A., Porto Salvo, Portugal, 2Novartis Farma-Produtos 
Farmacêuticos S. A., Portugal, Porto Salvo, Portugal
objeCtives: Portuguese financing model set for Multiple Sclerosis (MS) establishes 
a comprehensive price of 1.031,65€ per remitting patient/month. This study aimed 
to estimate global and individual direct costs of MS in Portugal and evaluate the 
coverage of MS Financing model for Relapsing-Remiting Multiple Sclerosis (RRMS) 
patients. Methods: A cost-of-illness (COI) approach was taken to assess direct 
costs/per RRMS patient by EDSS level, both for remission and relapse status using 
Delphi methodology for clinical practice measurement. Portuguese epidemiological 
data available for prevalence and relative distribution by EDSS level was used to 
estimate global MS costs and an average cost per RRMS patient. Results: The global 
cost for RRMS in Portugal is estimated to be approximately 83M€ /year for patients 
treated with 1st line Disease Modifying Therapies (DMT). Relapse treatment costs 
account for 8M€ . Direct costs estimated per disability level show that disability 
levels are directly related with expenditure in RRMS patients in remission (EDSS≤ 3: 
10.754,90€ ; 3,5≤ EDSS≤ 4,5: 20.113,99€ ; 5≤ EDSS≤ 6: 21.170,36€ ; EDSS≥ 6,5: 24.945,94€ ). 
The same was observed for relapse cost (EDSS≤ 3: 4.952,23€ ; 3,5≤ EDSS≤ 4,5: 5.568,49€ ; 
5≤ EDSS≤ 6: 8.801,03€ ; EDSS≥ 6,5: 9.265,31€ ). An average cost of 14.563,48€ per 
RRMS patient was estimated based on Portuguese EDSS epidemiological distribu-
tion. ConClusions: Current comprehensive financing model per patient does 
not cover the costs associated with an average RRMS patient. We demonstrated 
that considering the epidemiological distribution per EDSS level there is a gap of 
2.183,68€ (14.563,48€ vs. 12.379,80€ ). In addition, it was estimated that 2nd line high 
efficacy treatments (additional investment of 76% in treatment costs) may lead up to 
4.3M€ savings in relapse treatment total costs by reducing annualized relapse rate. 
Further studies should be developed to assess the budget impact of 2nd line high 
efficacy treatments on disability progression since lower EDSS scales are associated 
with less expenditure per patient (EDSS≤ 3: 10.754,90€ vs EDSS ≥ 6,5: 24.945,94€ ).
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objeCtives: Multiple Sclerosis (MS) is a chronic and progressive which represents 
a catastrophic payment to patient, society and health care system. Iran, differing 
to the other countries in Middle- east, is considered to have a medium to high 
prevalence of MS. Although much is known about the MS cost in the world, there 
is a very paucity of the MS cost study in Iran. The aim of study was to estimate the 
costs and QOL in MS individuals and determine whether these costs increase as 
disability progress. Methods: We studied 160 MS patients who attended in the MS 
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objeCtives: To assess the cost-effectiveness of abobotulinumtoxinA, onabotuli-
numtoxinA, incobotulinumtoxinA and local standard therapy (oral muscle relaxers) 
in patients with post-stroke spasticity in Russia for 1-year period. Physical therapy 
was used in all therapy schemes. Methods: A decision tree was used to simulate 
the effects of abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA and 
standard therapy. The data on drugs efficacy (measured as decrease in the Modified 
Ashworth scale (MAS) score) was obtained from available clinical trials [1-3]. The fol-
lowing costs were taken into account:, the costs of BTA and other drugs, costs of inpa-
tient and outpatient care in the Russian Federation, costs of adverse events, disability 
pensions, GDP loss due to post-stroke spasticity. Costs of BTA and other drugs were 
taken from the essential drug list and the database of drugs prices. Medical care costs 
were estimated from the Standard of treatment of stroke consequences developed by 
Ministry of Health of the Russian Federation. Costs of adverse events were calculated 
basing on Russian clinical guidelines and database of drugs prices. Disability pen-
sions were taken from Russian Pension Fund database. GDP loss was based on the 
GDP information from World Bank. Cost-effectiveness ratio (CER) of BTA and stand-
ard therapy was calculated and compared in four treatment schemes. Results: 
Therapy with abobotulinumtoxinA showed most prominent decrease of Modified 
Ashworth score equal to 1,67, as for onabotulinumtoxinA – 1,17, incobotulinum-
toxinA – 0,87, standard therapy – 0,67. The calculated CER in USD per 1 spastic-
ity decrease point according to MAS was lowest for abobotulinumtoxinA (389524 
RUB/11356 $) in comparison with onabotulinumtoxinA (635631 RUB/18532 $); inco-
botulinumtoxinA (798750 RUB/23287 $) and standard therapy (873312 RUB/25461 $). 
ConClusions: Therapy conversion to abobotulinumtoxinA comparing with stand-
ard therapy, onabotulinumtoxinA and incobotulinumtoxinA was associated with 
decrease of spasticity. Transfer to abobotulinumtoxinA is considered cost-effective 
in patients with post-stroke spasticity, given a cost-effectiveness ratio 389524 
RUB/11356 $.
PND27
cost coMPaRisoN of DeeP DRaiN stiMulatioN (DBs) aND coNtiNueD 
suBcutaNeous aPoMoRPhiNe iNfusioN (csai) iN PatieNts with 
aDvaNceD PaRkiNsoN’s Disease
Walleser Autiero S.1, Eggington S.1, Valyi A.2
1Medtronic International Trading Sarl, Tolochenaz, Switzerland, 2Medtronic Ltd UK & Ireland, 
Watford, UK
objeCtives: Deep Brain Stimulation (DBS) for the treatment of advanced 
Parkinson’s Disease (PD) is a therapy supported with high level evidence, however 
no direct comparative studies exist of DBS against other therapy options, such as 
continued subcutaneous apomorphine infusion (CSAI) exists. The objective of this 
study was to evaluate the 5-year cost profiles of two therapies for advanced PD, DBS 
and CSAI, from a UK payer perspective. Methods: A Markov model, previously used 
to model cost-effectiveness of DBS+BMT vs BMT alone (Eggington 2013), served to 
evaluate the cost profile of DBS and CSAI over five-years. Equal efficacy of the two 
therapies was assumed. The cost analysis covered: device acquisition, implanta-
tion, adverse event management, concomitant drug use, device replacements and 
follow-up. Cost data were taken from UK national tariffs, combined with device/
drug price lists and data from previous economic studies of interventions for PD. 
Disease-related inputs were based on recent studies of DBS and CSAI in patients 
with advanced PD, plus long-term data from the literature. Costs were discounted 
at 3.5% per annum. Results: Total discounted costs over 5 years were £69,566 and 
£80,843 for DBS and CSAI, respectively, leading to cost savings of £11,277 of DBS 
compared to CSAI over 5 years. DBS is cost saving compared to CSAI from 3 years 
onwards, with the initial costs of DBS device acquisition shown to be offset by the 
on-going provision of CSAI. ConClusions: The results indicate that DBS requires 
less health care resources than CSAI over five-years. Comparative clinical data are 
needed to formally assess the relative cost-effectiveness of the two interventions.
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objeCtives: To examine the health care utilizations and costs of long-term care 
facility patients diagnosed with Parkinson’s disease (PD). Methods: Patients 
diagnosed with PD (International Classification of Disease, 9thRevision, Clinical 
Modification [ICD-9-CM] diagnosis code 332) were identified using the Minimum 
Data Set (MDS) linked to 5% Medicare data from 01JAN2009 through 31DEC 2010. 
The initial diagnosis date was designated as the index date. A comparison cohort 
was created for patients without a PD diagnosis, using 1: 1 propensity score match-
ing (PSM) to control for age, region, gender, index year and baseline Charlson 
Comorbidity Index score. The index date for the comparison group was randomly 
chosen to reduce selection bias. Patients in both cohorts were required to be at 
least age 65 years, have at least two consecutive quarterly assessments in MDS 
data in the 6 months prior to the index date, and have continuous medical and 
pharmacy benefits 1 year before and after index date. Study outcomes, (health 
care costs and utilizations) were compared between the disease and comparator 
cohorts, based on the matched sample. Results: After applying PSM, a total of 
986 patients were included in each group (diseased and comparator cohorts), and 
baseline characteristics were balanced. A higher percentage of patients with PD 
had inpatient admissions (35.09% vs. 30.32%, p= 0.02), outpatient visits (93.91% 
vs. 89.45%, p< 0.001) and durable medical equipment (DME) utilization (27.69% vs. 
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apy. Methods: Observational, non-interventional, prospective, single-center study 
of 1 year follow-up from ITB implant onward. Results: 20 consecutive patients with 
ITB indication were recruited; 13 received an ITB implant during the study period; 
1 implant was rejected and thus explanted. 12 patients, of whom 10 had spasticity 
due to spinal-cord injury, 1 to multiple sclerosis and 1 to adrenoleukodistrophy, pro-
vided data for the study and 9 completed follow-up. After 12 months of ITB, mean 
changes from baseline were: -2.6 on the Penn scale (p= 0.011), -1.1 (p= 0.059) and -2.8 
(p= 0.011) on the Ashworth upper and lower scale, respectively and +4.4 on the FIM 
scale (p= 0.075). Mean utility gain, assessed with the HUI3 scale, was 0.054 (p= 0.091) 
after 1 year. Mean total ITB test and permanent implant cost per patient were € 528 
and € 14,225, respectively. Mean quarterly spending on oral antispastics decreased 
by € 42 at month 12, while consumption of intrathecal baclofen stabilized after 6 
months at € 39. At baseline, 4 patients received botulinum injections, while none 
did at the end of follow-up. Catheter-related adverse events occurred in 2 out of 12 
patients, with a total mean cost per event of € 2.387. While waiting to receive ITB, 
spasticity-related hospitalizations due to urological complications occurred in 2 out of 
20 patients, with a mean cost of € 9.044 per event; no such events were observed after 
ITB implant. ConClusions: Clinical outcomes of patients with N-FDS improved 
after ITB. Initial therapy costs were considerable, but were partially offset by savings 
in drugs and spasticity-related events after 1 year follow-up. Results should be inter-
preted cautiously because of the small number of observations.
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objeCtives: Pseudobulbar Affect (PBA) is a neurologic disorder of emotional 
expression, resulting in frequent and involuntary episodes of crying and/or laugh-
ing. Common neurological conditions associated with PBA include: Alzheimer’s 
disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, stroke 
and traumatic brain injury. Nuedexta® (Avanir Pharmaceuticals Inc.) is the only 
EMA-approved PBA treatment. The financial impact of introducing Nuedexta to 
a national health care system, including Scotland, has never been formally esti-
mated. Methods: An Excel® based cost-calculator was developed. Prevalence, 
epidemiology and mortality estimates for causative neurological conditions as 
well as PBA prevalence in those conditions were sourced from the literature. Unit 
costs (drugs, hospitalisation etc.) were taken from national databases and standard 
care treatment mix and resource use were derived from a US claims database. A 
range of market uptake rates were used with further sensitivity analyses under-
taken. Results: The estimated cost of standard care in Scotland for PBA is circa 
£32.4 million annually (circa 22,500 patients). In year 1 following introduction, 67 
patients are expected to receive Nuedexta, resulting in a cost increase by £0.1 mil-
lion to £32.5 million. By year five, 836 patients are estimated to receive Nuedexta, 
resulting in a projected total annual cost of £34.6 million. Therefore the estimated 
annual budget impact of Nuedexta ranges from £0.15 million (year 1) to £1.88 mil-
lion (year 5). The incremental cost per patient is £2,246. The model was sensitive 
to changes in uptake rates, cost of background therapy and PBA symptom severity. 
When patients with moderate to severe PBA symptoms receive treatment, the pro-
jected cumulative year 5 budget impact estimate is £7.56 million. ConClusions: 
The estimated financial impact of introducing Nuedexta in Scotland is modest. Even 
if more patients are identified, the relatively small incremental cost per-patient of 
Nuedexta is unlikely to have a major impact on the Scottish NHS.
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objeCtives: To analyze factors of recent evolution of Multiple Sclerosis (MS) Disease 
Modifying Therapies (DMT) budgets in Spain between 2004 and 2013. Methods: 
2004-2013 single DMT monthly expenditure was provided by IMS Health. Monthly and 
annually evolution of number of patients, billing, drug cost per patient and cost per 
year of treatment were calculated. Two periods: 2004-2013 and 2007 (start marketing 
second lines DMT) -2013 period were analyzed for each DMT line. (First line: subcutane-
ous and intramuscular interferon (IFN) β -1a, subcutaneous IFN β -1b and glatiramer acetate 
injection. Second line: natalizumab and fingolimod). Results: During 2004-2013 DMT 
expenditure increased from € 115.5M to € 319.3M due to: A greater number of patients 
147% (10.60 % annual growth per year) and a further growth of annual cost per patient: 
12% (1.29 % annual growth per year). In December 2013 second lines correspond to 
a 29.61% of DMT expenditure. Annual cost per patient in second line represents 70% 
over cost per treated patient and 83% greater than first line DMT cost per year. If 
year 2007 is omitted from analysis (Only 68 second-line treatments and M1.44€ of 
associated expense) and is analyzed 2008-2013 period, second-line DMT represent 
43% of new treatments causing a 60% increase in DMT expenditure. In 2013 second 
line DMT participation reaches 64% of new regimens causing the 79% of increase DMT 
expenditure. ConClusions: The growing incorporation of new therapies and the 
noticeable rise in the number of treated patients (10.60 % annual growth per year) are 
components to consider in the pharmaceutical budget management.
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objeCtives: Comprehensive economic costs of multiple sclerosis (MS) accord-
ing to EDSS states can only be assessed by evaluating MS management in real 
clinical practice. The objective of this cross-sectional study was to measure the 
association of Khorasan privence (the widest province in Iran ). Quality of life was 
measured with MSQOL-54 instrument. Data was collected by employing a 32- item 
self-administered questionnaire in a face to face interview. Parametric, nonpara-
metric tests and descriptive statistics analysis were applied (p value< 0.05). Patients 
were grouped into three disability stages according to their Expanded Disability 
Scale Score (EDSS). Results: The Patients mean age was 31.78 (SD: 9.67 ) years, 
% 73.8 were female and %26.3 were male, and their mean EDSS was 2.4 (SD; 1.26) 
whereas EDSS increases, the costs also increases, which is a positive correlation. 
The mean QOL was 0.54 that as QOL increases, the costs decreases, which is a nega-
tive correlation. The MS medications (Interferon) have a cost around $ 46625 per 
year for each patient that are subsidized about $ 24452 IR by governmental sector. 
Up to $ 17104 are paid by insurance and $ 5263 directly by patients. The costs per 
patient-year were calculated as $ 11560) - 27970.5591 (EDSS= 1-2.5), $ 29916.909- 
30015.645 (EDSS= 3-4.5) and $34678.776- 34793.22 (EDSS= 5- 7.5). ConClusions: 
We conclude that the costs are relevant in MS, especially when disability increases. 
The catastrophic cost has a high burden to patients, society and health care system
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objeCtives: The primary objective of this study is to elucidate the effect of whole 
exome sequencing (WES) in diagnosing children with a developmental delay due to 
unexplained conditions presumed to be genetic. A secondary objective is to collect 
all resources used by these children to gain insight into the total costs over time for 
the traditional diagnostic pathway and the additional costs to diagnose a patient 
using WES. Methods: We included twenty children at the Sylvia Toth Centre (STC) 
in Utrecht, the Netherlands, who have underwent previously extensive clinical diag-
nostic workups and for whom no diagnosis was found after the last extensive workup. 
On all twenty children and parents WES will be performed, thereby obtaining a list 
of exonic candidate mutations for each patient. In parallel all resources used were 
collected by assessing the clinical records of patients. These resources were linked 
to unit costs to obtain the total cost per patient. Total cost per patient was then com-
pared to the cost of care using WES, assessed for each individual patient. Results: 
The diagnostic yield from the 13 patients sequenced thus far is 23% indicating a 23% 
increase in number of diagnoses compared to the current diagnostic pathway. On 
average these patients have had numerous visits to the hospital, overnight stays 
and different diagnostic workups to unravel the genetic cause of their neurologi-
cal disorder. Total cost of the current diagnostic pathway is therefore up to ten fold 
higher compared to the total cost of only providing WES. ConClusions: Comparing 
the diagnosis and costs with and without the use of WES gives a clear picture of the 
clinical and economic feasibility of putting WES into standard diagnostic practice at 
the STC and similar genetic centers over the world.
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objeCtives: To estimate the clinical and financial impact of Interferon beta-1a 
intramuscular (IM) and subcutaneous (SC) formulations in Portugal, based on the 
findings from Cochrane review regarding first-line treatments for relapsing-remit-
ting multiple sclerosis. Methods: An Excel-based model estimated the number of 
relapses and costs incurred by a hypothetical cohort of 1000 patients treated with 
two types of interferon beta-1a. The model evaluated the consequences of treatment 
with SC versus IM interferon beta-1a, as this was the only comparison whose data 
quality was assessed as ‘high’ by the Cochrane Review (Filippini 2013). Risk of relapse 
was based on the 2-year data from the Cochrane meta-analysis. The analysis was 
performed from a Portuguese National Health Service (NHS) perspective including 
only direct costs. Although efficacy was kept constant as Cochrane did not report 
outcomes based on Expanded Disability Status Scale (EDSS), costs of relapse were 
available for patients with different EDSS values, thus allowing estimation of cost 
impact for different types of population. Results: According to the model, treat-
ment with IM interferon beta-1a is expected to result in a total of 743 episodes of 
relapse, whereas SC interferon beta-1a is expected to result in a total of 570 cases, 
less 173 cases, over a 2-year period. Use of the SC formulation in a population with 
EDSS ≤ 3 will result in savings of € 690,213.04 over the 2-year period due to avoided 
relapses. In a more severe population, with EDSS between 3.5 and 4.5, these savings 
are expected to be € 889,865.74 over the same 2-year period. ConClusions: When 
compared with the IM formulation, the use of SC interferon beta-1a seems to be 
associated with fewer cases of relapse, resulting over a 2-year period in considerable 
potential savings to the NHS in terms of relapses avoided.
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objeCtives: To assess clinical outcomes, health care resource utilization and asso-
ciated costs of intrathecal baclofen therapy (ITB) for the treatment of non-focal 
disabling spasticity (N-FDS) in patients who are resistant or intolerant to oral ther-
